Video

Cosmo Smith on How Origin Improves Patient Access

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.

Patients go to health systems for access to novel therapeutics, explains Smith, which is why Origin decided to partner with Atlantic Health. As Origin moves forward, they hope to embody a similar culture as that of Atlantic Health by providing access to the therapies that have the best chance of success to the greatest number of patients, says Smith.

Enabling that success is not an insignificant barrier, explains Smith. There needs to be a level of both excitement within the parent institutions as well as financial creativity. One of the missions at Atlantic Health is to create better therapeutic access to patients by looking at new insurance and payer structures. This is where Origin comes in, as they are heavily involved in those regards on an industry-wide basis. The goal, says Smith, is to have a variety of available health plans and carve out programs that allow patients access to the treatment they need when they need it.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center